高级检索
当前位置: 首页 > 详情页

Gambogic acid suppresses nasopharyngeal carcinoma via rewiring molecular network of cancer malignancy and immunosurveillance.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China [2]Graduate School of Guangxi Medical University, Nanning, China [3]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China [4]Life Science Institute, Guangxi Medical University, Nanning, China [5]School of Basic Medical Sciences, Guangxi Medical University, Nanning, China [6]Pharmaceutical College, Guangxi Medical University, Nanning, China [7]Institute of Biomedical Research, Yunnan University, Kunming, China
出处:
ISSN:

关键词: Gambogic acid Nasopharyngeal carcinoma Cancer repression Chemotherapy Immunotherapy

摘要:
Nasopharyngeal carcinoma (NPC) is a malignant tumor highly prevalent in Southeast Asia. The distant metastasis and disease recurrence are still unsolved clinical problems. In recent years, traditional Chinese medicine (TCM) monomers have become significantly attractive due to their advantages. Using high throughput drug sensitivity screening, we identified gambogic acid (GA) as a common TCM monomer displaying multiple anti-NPC effects. GA could effectively inhibit the proliferation of low differentiated cells and highly metastatic cells in NPC via inducing apoptosis and G2/M cell cycle arrest. In addition, GA obviously repressed the abilities of cell clone, migration, invasion, angiogenesis and represented satisfied synergistic effects combined with chemotherapy. Importantly, we found the elevated immune checkpoint CD47 stimulated after chemotherapy was dramatically impaired by GA treatment. Mechanically, the network pharmacology analyses unraveled that the oncogenic signaling pathways including STATs were rewired by GA treatment. Taken together, our study reveals a molecular basis and provides a rationale for GA application as the treatment regime in NPC therapy in future.Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 1 区 药学 2 区 医学:研究与实验
最新[2023]版:
大类 | 2 区 医学
小类 | 1 区 药学 2 区 医学:研究与实验
JCR分区:
出版当年[2020]版:
Q1 PHARMACOLOGY & PHARMACY Q1 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China
共同第一作者:
通讯作者:
通讯机构: [4]Life Science Institute, Guangxi Medical University, Nanning, China [5]School of Basic Medical Sciences, Guangxi Medical University, Nanning, China [6]Pharmaceutical College, Guangxi Medical University, Nanning, China [7]Institute of Biomedical Research, Yunnan University, Kunming, China [*1]Life Science Institute, Guangxi Medical University, Nanning, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)